HERE COMES TRUMP AND THE U.S. GOVERNMENT!

Discussion in 'Lundbeck' started by anonymous, Jul 8, 2019 at 6:35 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


  2. anonymous

    anonymous Guest

     
  3. anonymous

    anonymous Guest

    Lundbeck doesn’t offer rebates on its rare disease products. Just one more reason you psych lunatics are an inferior species that will soon die off.
     
  4. anonymous

    anonymous Guest

    Even so, I would bet we sell it a hell of a lot cheaper somewhere else in the world than we do here. If another country can get it at the bargain price of $100,000 (ridiculous amount!) a year or less, then that’s what we will have to price it in the U.S. Read the article. One way or another, all U.S. Pharmaceutical companies will have to match the price at the lowest price found in other countries. It will be a blow to revenue/profit. This will just be the beginning of price controls.
     
  5. anonymous

    anonymous Guest

    Lower the prices in the US?? Other countries will get theirs raised! Their low cost days are over.
     
  6. anonymous

    anonymous Guest

    There are ways around this, including our licensing molecules to entirely companies in the US. Rooting against your employer is dumb. If you hate the industry so much go someplace else.
     
  7. anonymous

    anonymous Guest

    There are ways around this, including out licensing molecules to entirely different companies in the US. Rooting against your employer is dumb. If you hate the industry so much go someplace else.
     
  8. anonymous

    anonymous Guest

    Don’t think your idea will work...at all. Prices will come down, of that there is no doubt. Don’t think anyone is rooting against the industry, but nobody can deny its greed. This will ripple through the industry causing layoffs.
     
  9. anonymous

    anonymous Guest

    C'mon people get real. Just take a look at Rexulti.It is NOT EVEN A ME TOO. It would be a me too if if was even as good as Abilify but it is not. It took 2 combined studies to get it thru for efficacy. It is no safer than anything else on the market. OK so if it isn't as good or isn't any safer, why is it priced higher? These types of decisions will end whether the company decides or the government decides for them.
     
  10. anonymous

    anonymous Guest

    Here comes the bill that will change the pharma industry forever, H.R. 3. It will save Americans hundreds of millions of dollars. It will also benefit seniors as well. Me-too drugs like we sell will find it hard going to compete. Companies that can’t innovate and discover real meaningful drugs will be in a world or hurt.

    Change in this industry is long overdue. If you can’t reinvent yourself, you will find yourself in a bad position if you want to stay in pharma.
     
  11. anonymous

    anonymous Guest

    im on a PAC committee. Bill is going to die in the Senate
     
  12. anonymous

    anonymous Guest

    You will have egg on your face!!
     
  13. anonymous

    anonymous Guest

    Also: Failed bipolar studies from what I've read. But yes, a me-too, and a very expensive one on top of that!!
     
  14. anonymous

    anonymous Guest

    Please let me know how that is supposed to be enforced!!
     
  15. anonymous

    anonymous Guest

    It was announced that we are not seeking a bipolar indication for Rexulti. Also, Takeda was told at their meeting that they would not seek any further indications for Trintellix. You have what you have until they go off patent.
     
  16. anonymous

    anonymous Guest

    Solid post. Would read again.
     
  17. anonymous

    anonymous Guest

    So sport, tell us, you'd yourself pay for these inflated drugs yourself?
     
  18. anonymous

    anonymous Guest

    Rexulti: no bipolar, no PTSD, no better than generic Abilify, no remission data, not much coverage. Again Glover, why should a doctor use a way too expensive me too called Rexulti??